Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 277 results for "Tecfidera Treated Patients"

New Biogen MS drug challenges Copaxone
Globes

Making Treatment Decisions When There Is an Abundance of Options

Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis (MS), the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, ... American Journal of Managed Care, 6 days ago
[x]  

1 images for "Tecfidera Treated Patients"

ABC News 4 Charleston, 1 month ago

New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients

Long-term Favorable Safety Profile Sustained in Patients Treated with TECFIDERA Positive Clinical and MRI Outcomes in Newly Diagnosed Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 11, 2014-- Today Biogen Idec (NASDAQ: BIIB) announced that ...
 BusinessWeek1 week ago Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA Provides Strong, Sustained Efficacy for RRMS  Benzinga.com1 week ago Biogen Idec's Phase 3 Study With Tecfidera Show Positive Data Over 5 Years  RTTNews.com1 week ago BIOGEN IDEC : New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients  4 Traders1 week ago
[x]  

New oral MS treatment Tecfidera approved for use in England and Wales

Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence (NICE) has announced. The NHS must now begin funding this treatment for eligible ...
 Multiple Sclerosis Society3 weeks ago

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

News Categories Clinical Trials Research News Industry Trends Agency
 Pharmscope1 month ago

TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERA is a first-line oral treatment for adults with ...
 MoneyShow.com1 month ago TECFIDERA(tm), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed  Finwin1 month ago
[x]  

Biogen Idec announces encouraging data from Phase III multiple sclerosis study

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS.
 Individual.com2 days ago

5 Things Biogen Idec Inc's Management Wants You to Know

1."Our core multiple sclerosis franchise performed remarkably well, and we continue to see an increasing number of patients using our therapies." -- George Scangos, Biogen Idec's CEO When Biogen Idec launched its oral multiple sclerosis drug ...
 Motley Fool2 weeks ago
Boston Globe

FDA okays Genzyme pill for Gaucher disease

Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...
 Boston Globe1 month ago
Boston Globe

FDA approves new injectable multiple sclerosis treatment from Cambridge's Biogen Idec

Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won US regulatory approval Friday to sell a new type of injectable drug that treats adults with the most common form of the ...
 Boston Globe1 month ago Market Update: Biogen Idec Inc (NASDAQ:BIIB) Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process)  Jutia Group1 week ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub  Jutia Group3 weeks ago Forward Pharma looks ahead to Wall Street IPO  M&A Portal1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less